Laboratory of Nano-Biotechnology, Division of Bioengineering and Drug Discovery, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan.
Division of Biochemistry, Chemistry Department, Faculty of Science, Menoufia University, Menoufia, Egypt.
Cell Biol Int. 2021 Apr;45(4):749-756. doi: 10.1002/cbin.11511. Epub 2020 Dec 21.
Angiogenesis is generally involved in tumor growth and metastasis. Cancer stem cells (CSCs) are considered to facilitate the angiogenesis. Therefore, CSCs could be the effective targets to stop angiogenesis. Recently, our group successfully generated CSC models from induced pluripotent stem cells (iPSCs) in the presence of conditioned medium derived from cancer derived cells. These novel model CSCs has been characterized by highly tumorigenic, angiogenic and metastatic potentials in vivo. The angiogenic potential of CSCs has been explained by the expression of both angiogenic factors and their receptors implying the angiogenesis in autocrine manner. In this protocol we optimized the method to evaluate tumor angiogenesis with the CSC model, which was described effective to assess sorafenib as an antiangiogenic drug, on chick chorioallantoic membrane (CAM) assay. Our results demonstrate that CSCs developed from iPSCs and CAM assay are a robust and cost-effective tool to evaluate tumor angiogenesis with CSCs. Collectively, CSCs in CAM assay could serve as a very useful model for the screening of potential therapeutic agents targeting tumor angiogenesis.
血管生成通常涉及肿瘤的生长和转移。癌症干细胞（CSC）被认为有助于血管生成。因此，CSC 可能是阻止血管生成的有效靶点。最近，我们的研究小组成功地在源自癌细胞的条件培养基存在下，从诱导多能干细胞（iPSC）中生成 CSC 模型。这些新型模型 CSC 具有高度的致瘤性、血管生成和体内转移潜能。CSC 的血管生成潜能可以通过表达血管生成因子及其受体来解释，这意味着血管生成是自分泌的方式。在本方案中，我们优化了使用 CSC 模型评估肿瘤血管生成的方法，该方法已被证明可有效地评估索拉非尼作为抗血管生成药物在鸡胚尿囊膜（CAM）试验中的作用。我们的结果表明，源自 iPSC 和 CAM 试验的 CSC 是评估 CSC 肿瘤血管生成的强大且具有成本效益的工具。总之，CAM 试验中的 CSC 可以作为一种非常有用的模型，用于筛选针对肿瘤血管生成的潜在治疗剂。
